{"id":"W3135839740","doi":"10.1200/jco.2021.39.6_suppl.314","title":"Health-related quality-of-life outcomes from a phase II open-label trial of two different starting doses of lenvatinib in combination with everolimus for treatment of renal cell carcinoma following one prior VEGF-targeted treatment.","year":2021,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Renal cell carcinoma treatment","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"ca_institutions":"University of Calgary","funders":"","keywords":"Medicine; Lenvatinib; Everolimus; Renal cell carcinoma; Clinical endpoint; Internal medicine; Quality of life (healthcare); Oncology; Kidney cancer; Clinical trial; Phases of clinical research; Cancer","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.005038362,0.001612127,0.002410718,0.000423727,0.0006229004,0.001117931,0.001035825,0.001557305,0.003677266],"category_scores_gemma":[0.003389654,0.0005475109,0.002948248,0.000477911,0.001184128,0.001141207,0.0006767064,0.004853835,0.0006936425],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.001206514,"about_ca_system_score_gemma":0.001806738,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0007305507,"about_ca_topic_score_gemma":0.001592229,"domain_scores_codex":[0.9979602,0.001177923,0.0001342759,0.0003022994,0.0001825683,0.0002425858],"domain_scores_gemma":[0.9958061,0.001013446,0.001291583,0.0003298504,0.0003089575,0.001250084],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","study_design_scores_codex":[0.9548258,0.02494492,0.004148494,0.0002606091,0.001855659,0.00003872626,0.00006542424,0.0008270994,0.003315574,0.00004748525,0.0009803089,0.008689845],"study_design_scores_gemma":[0.7023201,0.2729515,0.02056566,0.00002693812,0.001262209,0.00006792534,0.00003311556,0.0008656649,0.001126052,0.0001140589,0.0006361461,0.00003057597],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9937562,0.001143784,0.0002774482,0.0002684511,0.0001018294,0.00170523,0.001980285,0.000025285,0.0007414625],"genre_scores_gemma":[0.987537,0.0005322461,0.0009950956,0.0005853409,0.0002312316,0.003619008,0.005701287,0.00001559952,0.0007833515],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.005038362,"threshold_uncertainty_score":0.02664572,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.337874391333938,"score_gpt":0.5052543612984711,"score_spread":0.1673799699645331,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}